Patents by Inventor Aiden Haghikia

Aiden Haghikia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11865091
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 9, 2024
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 11602510
    Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 14, 2023
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventor: Aiden Haghikia
  • Patent number: 11471432
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: October 18, 2022
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20220313634
    Abstract: The invention relates to an agent for use in the prophylactic and/or supportive therapeutic treatment of Parkinson's disease, said agent comprising a physiologically effective amount of propionic acid and/or butyric acid and/or physiologically compatible salts or esters thereof.
    Type: Application
    Filed: June 20, 2022
    Publication date: October 6, 2022
    Inventors: Horst Przuntek, Aiden Haghikia
  • Publication number: 20200323802
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 15, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20200289442
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Application
    Filed: June 3, 2020
    Publication date: September 17, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ralf Linker
  • Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Patent number: 10682322
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 16, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & GO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Publication number: 20200163914
    Abstract: The invention relates to an agent for use in the prophylactic and/or supportive therapeutic treatment of Parkinson's disease, said agent comprising a physiologically effective amount of propionic acid and/or butyric acid
    Type: Application
    Filed: July 13, 2018
    Publication date: May 28, 2020
    Inventors: Horst Przuntek, Aiden Haghikia
  • Publication number: 20200138875
    Abstract: The invention relates to an agent for use in the treatment of diseases due to an imbalance of the microbiome, in particular multiple sclerosis (MS) and Parkinson's disease, in the form of a microbiome transplant to be administered to the patient to be treated, wherein the microbiome transplant being obtainable from the stool of one or several healthy subjects through extraction with an aqueous medium, concentration of the extract and packaging to obtain a transplantable concentrate.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 7, 2020
    Inventors: Horst Przuntek, Aiden Haghikia
  • Publication number: 20200030267
    Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.
    Type: Application
    Filed: March 9, 2018
    Publication date: January 30, 2020
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventor: Aiden Haghikia
  • Publication number: 20180303778
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Application
    Filed: July 8, 2016
    Publication date: October 25, 2018
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ulrich Matthes
  • Publication number: 20170231933
    Abstract: The invention relates to an agent supporting the immunomodularity for the treatment of autoimmune diseases, said agent containing C3-C8 carboxylic acids, their physiologically tolerable salts and/or esters with C1-C8 alkyl alcohols, their use as supporting immunomodulators for autoimmune related diseases and immune-mediated chronic inflammatory diseases, as well as dietary supplements with immunomodulating effect containing these.
    Type: Application
    Filed: October 19, 2015
    Publication date: August 17, 2017
    Applicant: Flexopharm Brain GMBH & Co. KG
    Inventors: RALF GOLD, Aiden Haghikia, Ralf Linker
  • Publication number: 20150267254
    Abstract: The invention provides a method of determining if a patient is afflicted with multiple sclerosis (MS) using microRNA (miRNA) profiles of specific miRNAs that are present in the cerebrospinal fluid (CSF). This method can also be used to discriminate different forms of MS. The invention further comprises a kit for diagnosing or monitoring MS based upon the miRNA profiles according to the invention, and also relates to the use of said miRNA profiles in the diagnosis or monitoring of MS.
    Type: Application
    Filed: July 5, 2013
    Publication date: September 24, 2015
    Applicants: MEDIZINISCHE HOCHSHULE HANNOVER, ST. JOSEF - UND ST. ELISABETH HOSPITAL GMBH
    Inventors: Thomas Thum, Aiden Haghikia, Arash Haghikia, Ralf Gold